Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
Bonjoch A, Paredes R, Domingo P, Cervantes M, Pedrol E, Ribera E, Force L, Llibre JM, Vilaró J, Dalmau D, Cucurull J, Mascaró J, Masabeu A, Pérez-Alvarez N, Puig J, Cinquegrana D, Clotet B. Bonjoch A, et al. Among authors: ribera e. AIDS Res Hum Retroviruses. 2006 Apr;22(4):321-9. doi: 10.1089/aid.2006.22.321. AIDS Res Hum Retroviruses. 2006. PMID: 16623634
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
Ochoa de Echagüen A, Arnedo M, Xercavins M, Martinez E, Rosón B, Ribera E, Domingo P, González A, Riera M, Llibre JM, Gatell JM, Dalmau D; Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team. Ochoa de Echagüen A, et al. Among authors: ribera e. AIDS. 2005 Sep 2;19(13):1385-91. doi: 10.1097/01.aids.0000181010.85255.3c. AIDS. 2005. PMID: 16103769 Clinical Trial.
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group. Mallolas J, et al. Among authors: ribera e. J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f. J Acquir Immune Defic Syndr. 2009. PMID: 19390327 Clinical Trial.
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, Puig J, Mateo MG, Podzamczer D, Gutierrez MM, Paredes R, Clotet B, Gatell JM, Blanco JL, Martínez E; DOLAM study group. Rojas J, et al. Among authors: ribera e. Lancet HIV. 2021 Aug;8(8):e463-e473. doi: 10.1016/S2352-3018(21)00100-4. Lancet HIV. 2021. PMID: 34358497 Clinical Trial.
[Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions].
Pedrol E, Martín T, del Pozo MA, Flores J, Sanz J, Cartón JA, Jusdado JJ, Arazo P, Ribera E, Deig E; Grupo de Estudio de Evaluación del uso de Análogos de Nucleósidos. Pedrol E, et al. Among authors: ribera e. Med Clin (Barc). 2007 Sep 22;129(10):361-5. doi: 10.1157/13110209. Med Clin (Barc). 2007. PMID: 17915129 Spanish.
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review.
Palacio-Vieira J, Reyes-Urueña JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaró I, Borràs FH, Falcó V, Riera M, Domingo P, de Lazzari E, Miró JM, Casabona J; PICIS study group. Palacio-Vieira J, et al. BMC Public Health. 2021 Aug 28;21(1):1596. doi: 10.1186/s12889-021-11613-y. BMC Public Health. 2021. PMID: 34454444 Free PMC article. Review.
352 results